Guardians at the gate: Biosimilar and patent reform legislation could fundamentally change the guards for therapeutic monoclonal antibodies--Part 2.
Patent protection and FDA exclusivities are the two principal forms of protection available to companies that develop therapeutic monoclonal antibodies. Propo-sed changes to both forms of protection are currently being debated in the United States Congress. Specifically, Congress is presently debating both biosimilar and patent reform legislations. Although no bill has yet passed, it is expected that patent reform legislation should pass this year. It is less likely that a biosimilar bill will pass this year. However, when legislations are enacted, the changes will significantly impact the business of therapeutic monoclonal antibodies.
McCabe
Kevin W
KW
Sterne, Kessler, Goldstein & Fox, P.L.L.C., Washington, DC, USA. kmccabe@skgf.com
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007878:Legislation as Topic; D007880:Legislation, Drug; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D000911:Antibodies, Monoclonal